A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis
Public ClinicalTrials.gov record NCT00265096. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy (improvement of signs and symptoms) of subcutaneous (under the skin) injections of golimumab for the treatment of active psoriatic arthritis (PsA). Efficacy will be measured by reduction in the signs and symptoms of active PsA, including effects on joint pain and swelling, changes on x-ray related to joint damage, psoriasis skin lesions, physical function, and quality of life.
Study identification
- NCT ID
- NCT00265096
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 407 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2005 (Type not available)
- Primary completion
- May 2007 (Actual)
- Completion
- Jan 2012 (Actual)
- Last update posted
- Jul 19, 2013
2005 – 2012
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | — | — |
| Not listed | La Jolla | California | — | — |
| Not listed | Upland | California | — | — |
| Not listed | Aventura | Florida | — | — |
| Not listed | Coeur d'Alene | Idaho | — | — |
| Not listed | Kansas City | Kansas | — | — |
| Not listed | Wheaton | Maryland | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Mayfield | Ohio | — | — |
| Not listed | Lake Oswego | Oregon | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Duncansville | Pennsylvania | — | — |
| Not listed | West Reading | Pennsylvania | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Edmonds | Washington | — | — |
| Not listed | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00265096, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 19, 2013 · Synced Nov 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00265096 live on ClinicalTrials.gov.